EMA Withdrawn: Bondenza (previously Ibandronic Acid Roche) (ibandronic acid) — Roche Registration Ltd.

View source ↗

Summary

The EMA indicates that Bondenza (ibandronic acid) has been withdrawn from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Bondenza (ibandronic acid)

Snippet

Status: Withdrawn. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Roche Registration Ltd.. Decision date: 15/11/2012